Elegant Solutions for Complex Challenges
ViQi has successfully trained AIs for multiple forward-thinking labs at large pharmaceutical companies, CRO/CDMOs, biotech start-ups, and academic institutions. These labs are focused on a broad range of viral infectivity assay applications in R&D, bioprocessing, cell/gene therapy, oncolytic viral immunotherapy, viral clearance, and manufacturing.
Our flexible solution has demonstrated effectiveness in a number of cell-based R&D projects. With our flagship product, AVIA™, we've shown a more streamlined, precise approach to measuring viral infectivity on a diverse array of viruses, encompassing both RNA and DNA viruses, as well as enveloped and non-enveloped types. With a proven track record of success against over 20 different viruses, multiple cell lines, and various imaging devices, we are confident in our ability to provide a reliable and effective solution tailored to your specific requirements.
We understand the importance of developing a rigorous assay that can meet regulatory demands, including GMP-readiness. We work closely with our customers to support proper validation of the assay according to ICH guidelines. Our ISO27001 certified platform provides the necessary peace of mind to know that your data and results are securely managed on the ViQi platform.
We will be your Guide in Unlocking the Power of AI in Reimagining your
Analytical Bioassays.
Viral infectivity in as little as a day.
ViQi’s Automated Viral Infectivity Assay (AVIA™) is an AI-based assay that uses machine learning and brightfield microscopy to detect phenotypic changes associated with viral infection prior to visible CPEs without requiring intensive genetic engineering of proxy signals (e.g., fluorescence).
Plaque Assays
TCID-50s
Fluorescent Labeling
Replaces
Titration
Inactivation
Neutralization
Viral Clearance
Applies to
AVIA Advantage
ViQi customers are first interested in AVIA for its increased capacity and then are further impressed by AVIA’s superior precision and numerous other benefits:
Viral infectivity confirmation in under 2 days
Precision of ± 20%
10x+ increase throughput with automation
More cost-effective and sustainable
No staining required
Significant advantages with BSL3/BSL4 viruses
Requires less training and no prior experience
Some of our AVIA Partners
Working Together is Easy
The ViQi team understands the importance of a streamlined and validated assay setup process. We collaborate with you to develop a tailored experimental protocol for your specific virus and cell line, considering the unique requirements of your laboratory. We will assist in the proper configuration of your automated imager and work closely with your IT team to ensure secure data uploads to our Amazon Web Services account.
Your Role
ViQi’s Role
Image 96-well plates in brightfield. Imaging time is 5-40 minutes per plate depending on the imager model.
Provide imaging and IT support to meet technical requirements and ensure a seamless workflow.
Transfer your image files and experimental metadata to ViQi’s platform using our convenient drag-and-drop feature.
Access ViQi’s Software-as-a-Service (SaaS) platform through a standard web browser to view the provenance of all analysis results and stored images
Interested in a demo?
It takes less than 2 weeks to see how AI can accelerate your infectivity assay.
Train and validate a customized AI model.
Deliver analytical reports within one hour using trained AI models
Provide a customized experimental protocol.
Provide your own cells, viruses and automated imager.